August 23rd 2023
Verrica’s statement follows the FDA’s warning from June 1, 2023.
Clinical ConsultationsTM: Focusing on Fabry Disease in Females: Individualizing Diagnostic and Counseling Plans to Improve Long-Term Outcomes
View More
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
Live Patient, Provider, and Caregiver Connection™: Prevention and Control of Meningococcal Disease – Individualizing Vaccine Recommendations in Adolescent Populations
10/22/2023
Register Now!
Expert Illustrations and Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
Register Now!
2nd Annual International Congress on Pediatric Oncology
View More
Best Practice in the Multidisciplinary Care of the Patient with HS
View More
Addressing Challenges in the Management of HS in Special Populations
View More
Patient, Provider, and Caregiver Connection™: Challenges in Diagnosis and Management for Patients with ADHD During the COVID-19 Pandemic
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Cases and Conversations™: Enhancing Diagnosis and Evaluation of Generalized Pustular Psoriasis in Advanced Practice Settings
View More
Clinical ShowCase™ in Atopic Dermatitis: Personalized Management Plans for Pediatric Patients
View More
Community Practice Connections™: Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy
View More
20th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Facing the Changing Landscape for Neuromodulators and Dermal Fillers
View More
FAQs in Peanut Allergy: Exploring Unanswered Questions Following Allergy Meeting Updates
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
Respiratory Syncytial Virus: Understanding the Infection Burden and Anticipating the Impact of Vaccines
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
Pediatric dermatology workforce challenge
April 1st 2008The training's tough, hours can be long, and the pay ... not usually as high as what other dermatologic subspecialists make; still, pediatric dermatologists contend that the career offers doctors challenging options in dermatology and the chance to impact children's quality of life.
Off-label treatments play potential role in management of HOIs
January 1st 2008Systemic corticosteroids ormedical intervention is indicated for hemangiomas of infancy. Recenliterature reports describe favorable experience with off-label use of imiquimod cream 5 percent (Aldara, Graceway), becaplermin gel 0.01percent (Regranex, Ortho-McNeil) and vincristine.
Nurses better at treating childhood eczema than dermatologists, study finds
November 6th 2007Melbourne, Australia - An Australian study suggests that nurses may be more effective in reducing the severity of atopic eczema in infants, children and adolescents than those treated by a dermatologist, ReutersHealth reports.
FDA advisory impacts treatment practice patterns for atopic dermatitis in babies
October 1st 2007A retrospective, longitudinal cohort study was undertaken to analyze the effects of the FDA advisory on off-label topical calcineurin inhibitor (TCI) treatment practice patterns for infants with atopic dermatitis (<2 years of age). The results show a reduction in overall utilization of AD-related medications and reduced utilization of TCIs coupled with early introduction of topical corticosteroid treatment after the advisory compared to the period preceding the advisory.
FDA issues new warning on asthma drug Xolair
March 5th 2007Washington - The Food and Drug Administration (FDA) has issued a new warning about omalizumab, an asthma drug marketed by Genentech as Xolair, and has requested that the manufacturer add “black box” warnings to the product’s label reflecting the risk of anaphylaxis.
'Active' moisturizers key to happier skin
March 1st 2007Pittsburgh - New "activated" moisturizers help the skin retain moisture, and they also repair abnormalities with the skin at baseline in atopic dermatitis patients, according to Douglas W. Kress, M.D., of Children's Dermatology Services at Children's Hospital of Pittsburgh.
Stiefel acquisition marries technology, marketing
March 1st 2007Coral Gables, Fla. - Stiefel Laboratories' recent purchase of Connetics blends Connetics' innovative vehicle technology with Stiefel's worldwide marketing reach, company officials say. For dermatologists and patients, the acquisition augurs a steady stream of new applications for vehicles including the popular, patient-friendly foam pioneered by Connetics.
New drugs' OK process lengthy, costly
February 1st 2007National report - The Food and Drug Administration's role is a necessary one, dermatologists say, but regulatory red tape can slow the introduction of new drugs into the marketplace, and post-marketing restrictions can hamper efforts to deliver effective medications to patients.
'Fishy' symptoms should spur referral
February 1st 2007Omaha, Neb. - A patient presenting to a primary care physician with complaints of an arm rash may not be particularly unusual, but one unusual case illustrates the need for proactive cooperation between primary care physicians and specialists to best serve the patient's needs.